Dirk T.
- Country
- Germany
- Department
- Hämatologie
Research Overview
- Phase 3 Randomized Study of Bendamustine, Rituximab, and Acalabrutinib in Untreated Mantle Cell Lymphoma
- Evaluation of BrECADD Versus Escalated BEACOPP in First-Line Treatment of Advanced Hodgkin Lymphoma: A Randomized Controlled Trial
- HU-F-AIM - A prospective, interventional study to evaluate HU-resistance in polycythemia vera patients who meet predictive parameters identified in the machine learning project PV-AIM
Data & Insights
Has run more than one trial at 11 of 232 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating lymphoid neoplasms and related blood disorders, with particular expertise in Hodgkin Lymphoma management and therapeutic innovations.
- Advanced Stage Hodgkin Lymphoma Treatment
- Treatment-Related Morbidity Assessment
- PET-Guided Therapy Approaches
Their work encompasses evaluation of novel therapeutic combinations and treatment optimization strategies.
Myeloproliferative Disorders
The investigator focuses on polycythemia vera treatment approaches, incorporating innovative diagnostic and therapeutic strategies using artificial intelligence applications.
- Hydroxyurea Resistance Patterns
- Predictive Risk Factor Analysis
- Machine Learning Applications in Treatment
Their research integrates advanced technological approaches with clinical practice in myeloproliferative disorders.
Non-Hodgkin Lymphoma
The investigator conducts research in mantle cell lymphoma treatment, focusing on combination therapy approaches and novel therapeutic agents.
- First-line Treatment Strategies
- Novel Agent Combinations
- Treatment Response Assessment
Their work involves evaluation of targeted therapies in combination with established treatment regimens.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.